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Abstract  
BACKGROUND: Hepatitis C is a blood-borne, infectious, viral disease that is caused by a 
hepatotropic virus called Hepatitis C virus (HCV).  
AIM: The aim of this study is to determine the prevalence of active HCV infection (HCV–RNA) in 
the cases that were anti-HCV positive.  
MATERIAL AND METHODS: Plasma of 301 high-risk for HCV infection consecutive from 
University Hospital Centre “Mother Theresa” Tirana-Albania, during January 2007 to December 
2010 was included in this study. To identify the presence of HCV RNA, the samples were examined 
by Cobas Amplicor HCV test (qualitative method).  
RESULTS: From 301 samples analyzed in total, 214 of them resulted positive for the presence of 
HCV-RNA's, corresponding to a prevalence of 71.1%, with 95% CI interval [65.8 - 75.9] for value of 
χ
2
 = 52.7 p value <0.0001. Divide by the sex 56% were males and 44% females, with statistically 
significant difference between them for value χ
2 
=4306 p value=0.0380. Among the age groups the 
highest prevalence was observed in the age groups > 25 years with a significant difference with 
other age groups for p value <0.001. 
CONCLUSION: Among tested samples, 71.1 % were confirmed to be positive for HCV –RNA 
infections. The prevalence of male was highest compared to female. For males and females 
infected the prevalence was highest in the age group of > 25 years. 
 
 
 
 
 
Introduction 
Human hepatitis C is an infectious disease 
affecting the liver of humans and chimpanzees, 
caused by the Hepatitis C Virus (HCV) [1]. HCV is the 
only known member of the Hepacivirus genus in the 
family Flaviviridae. It is single stranded 50 nm positive 
sense RNA virus with six major genotypes causing 
hepatitis C in the whole of the world [2, 3]. It is 
reported that approximately 15-40% of persons 
infected with HCV clear the virus from their bodies 
during the acute phase of infection and the 60-85% of 
patients infected with HCV develops chronic hepatitis 
C [4], which progresses to liver cirrhosis with an 
elevated risk of the development of hepatocellular 
carcinoma [2, 5, 6]. The infection is often 
asymptomatic especially in its early stages but once 
established, it can progress to advanced liver 
diseases such as liver fibrosis and ultimately cirrhosis. 
These liver diseases can further lead to other 
complications such as liver failure and liver cancer [7]. 
Albania, a developing nation with about 3 
million people has alarmingly rate of outbreaks of 
hepatitis C virus that need for proper survey and 
genotyping. Prevalence studies of anti-HCV 
antibodies in the general population of Albania have 
been recorded as about 1%. In the healthy population 
(200 samples) more the 15 years old the prevalence 
result 0.99% [8]. For the blood donor population in 
Albania the prevalence of Hepatitis C result to be 
0.7% [9].  
HCV-infection was never investigated at 
molecular level for presence of active infection in 
Albania so for this reason we did this study to 
determine the prevalence of active HCV infection 
(HCV–RNA) in the cases that were anti-HCV positive. 
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Materials and Methods 
Patients and blood sampling  
Plasma of 301 high-risk for HCV infection 
consecutive from different departments of University 
Hospital Centre “Mother Theresa” Tirana-Albania 
during January 2007 to December 2010 was included 
in this study. Patients comprise 169 men and 132 
women from different age groups (1-73 years of age). 
This plasma was examined for Hepatitis C to 
Molecular Biology Laboratory, Institute of Public 
Health, in Tirana. Patients belong to different groups 
from politransfusion persons, blood donation centers, 
and persons from Unit of Gastrohepatology and 
Infection Disease. Each individual duly signed a 
proforma containing information about his/her 
previous exposure to a risk factor like age, sex etc. 
The blood sample 5 ml of each patient was collected 
in EDTA-tubes and immediately was transported to 
Molecular Biology Laboratory, Institute of Public 
Health, for plasma isolation. Plasma samples aliquot 
were stored at -70
o
C until use. 
Note: the samples taken from politransfusion 
group included three categories: persons with 
Thalassemia, persons who have undergone process 
of dialysis and those who have hospitalized in onco-
hematology unit.  
 
HCV qualitative test 
The samples were subjected for molecular 
analysis. In this study we have identify the presence 
of HCV RNA by Cobas Amplicor HCV test, Roche 
Diagnostics GmbH, Mannheim, (qualitative method) 
that realizes the extraction of RNA from patient 
samples. This test is based on five major processes: 
specimen preparation; reverse transcription of the 
target RNA to generate complementary DNA (cDNA); 
PCR amplification of target cDNA using HCV specific 
complementary primes; hybridization of the amplified 
product to oligonucleotide probes specific to the 
target; and detection of the probe-bound amplified 
products by colorimetric determination according to 
the manufactures instruction by Roche [10].  
 
The method of data analysis 
Standard methods of statistical analysis 
SPSS 16 were used to assess the association 
between the study variables. Categorical variables 
were explored by using table 2x2 and chi-square. 
Observations for missing values were not included in 
the testing. Continuous variables were explored using 
Student t test two-way and one-way, OR with 95% CI 
waste oils and tailored for each model is reported. The 
level of significance is: α ≤ 0.05 
 
 
Results  
From 301 cases analyzed for HCV-RNA 56% 
of them were income from Gastro-Hepathology and 
Infection Disease Unit. In second place was the center 
of hemodialysis with 16.7% of cases, followed by 
center of thalasemia with 11.7% of cases (Table 1). 
Table 1: Number of cases divided by source of samples. 
Source of samples Number of cases Percentage 
Blood donors 17 5.60% 
Child's home 1 0.30% 
Prison 1 0.30% 
Hemodialysis 50 16.70% 
Pediatric 26 8.70% 
Drug users 2 0.70% 
Thalasemia 35 11.70% 
Gastrohemathology and Infection 
Desease Unit 
169 56.00% 
Total 301 100% 
 
From 301 samples analyzed in total, 214 of 
them resulted positive for the presence of HCV RNA's, 
corresponding to a prevalence of 71.1%, with 95% CI 
interval [65.8 - 75.9] for value of χ
2
 = 52.7 p value 
<0.0001 (Figure 1). 
 
Figure 1: Number of positive/negative cases in total. 
 
In this study, 56% (169) of cases were males 
and 44% (132) females. Men make up majority of the 
sample, with statistically significant difference with 
women. For value χ
2
 = 4306 p value = 0.0380. In this 
study the prevalence to men was highest compared to 
female. For male prevalence was 58% (124) while for 
female was 42% (90) cases. There were a significant 
value was show between the positive cases divided 
by sex. For value χ
2 
= 0.74 p value <0.049 (Figure 2).  
 
Figure 2: Positivity of cases divided by sex. 
 
Vila Brunilda et al. Prevalence of Hepatitis C Virus in the Population of Albania (2007-2010) 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Sep 15; 2(3):525-528.                                                                                                                                                                         527 
 
For 19 patients the data of age are missing. 
Age less taken in the study is <1 year, while the oldest 
age obtained in the study is 73 years. For this sample 
the average was 32.3 years, while the median is 30.5 
years. Value 95% CI for age group observed is [30.1-
34.5] (Figure 3).  
 
Figure 3: Distribution of cases divided by groups-age. 
 
 
Discussion  
WHO estimated the global prevalence of 
Hepatitis C as 3% [11]. Moreover, around 3 to 4 
million individuals are diagnosed as new cases every 
year [12]. Anti-HCV assays have several 
disadvantages, such as a high rate of false positivity, 
a lack of sensitivity of detection in the early window 
period of 45 to 68 days after infections, the inability to 
distinguish between acute (ongoing active, viremic), 
past (recovered), and persistent (chronic) infections, 
and a possibility of false negativity with samples from 
immunocompormised patients, who may an adequate 
antibody response [13, 14, 15, 16]. PCR has emerged 
as a powerful molecular diagnostic tool for the 
detection of active infection which is manifested by the 
presence of HCV RNA in the blood of the infected 
person. Until now no study had earlier been 
conducted to figure out the prevalence of anti-HCV 
antibodies especially for HCV-RNA among the 
general population of Albania. We for the first time 
conducted our study to find out prevalence of active 
HCV infection.  
Our study is descriptive and consisted in the 
collection of microbiological data from 2007 to 2010 
for 301 patients presenting to visit or hospitalized in 
the politransfusion persons, blood donation centers, 
and persons from Unit of Gastro-hepathology, 
Pediatric, and Infection Disease etc. Patients belong 
to a different status socio-economic, urban or rural 
residence. We note that all cases analyzed for HCV-
RNA were positive for anti-HCV, tested by 
immunoassay ELISA method. 56% of patients were 
income from Gastro-Hepathology and Infection 
Disease. Patients who manifest clinical signs like 
Hepatitis infection first of all went to Gastro-
hepathology and Infection Unit. For this reason we 
observed a significant difference between sources of 
samples (Table 1).  
From 301 anti-HCV positive only 214 of them 
resulted positive for the presence of HCV RNA's, 
corresponding to a prevalence of 71.1%. A difference 
between the cases of anti-HCV positive by ELISA and 
HCV-RNA positive cases and connects with sensitivity 
and higher specificity molecular methods and/or the 
spontaneous viral clearance of the virus. Following 
acute infection the overall rate of spontaneous viral 
clearance is estimated to be 25%, but appears to be 
dependent on the route of transmission and other host 
and pathogen-related characteristics (17-20). 
In this study 56% of cases were males and 
44% females. Men make up majority of the sample, 
with statistically significant difference with women. 
Such a significant difference is observed in a study 
conducted in the years 1999-2002 (21) (Figure 2). The 
least incidence of HCV in females could be attributed 
to low exposure to HCV risk factors due to male 
dominating society of the area and also the estrogens 
hormone in females is considered to play a role in the 
spontaneous clearance of HCV infection (22-24). 
Most patients belong to the age group > 25 
years. This groups present a significant difference 
with other age groups for p value <0.001. Higher 
prevalence in this age group may be linked to a 
sexually active age or/and almost of them have done 
surgical intervention or have done blood transfusion 
(Figure 3). 
In conclusion, the prevalence of active HCV 
(presence of HCV-RNA`s) recorded to different ages 
and gender groups show to be 71.1% and has 
increased with the increase of ages. The prevalence 
of active HCV to male was highest compared to 
female. In this study the prevalence results to be 
highest for the age group > 25 years.  
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